Short answer · Medically reviewed summary · Last updated: 2026-05-08
Hurler Syndrome (MPS1H) is a severe metabolic disorder caused by a deficiency in the enzyme alpha-L-iduronidase, which is essential for breaking down complex sugars called glycosaminoglycans (GAGs). This deficiency is caused by mutations in the IDUA gene, resulting in the toxic accumulation of GAGs within the body's cells and tissues. What causes Hurler Syndrome (MPS1H) at a genetic level? Hurler Syndrome (MPS1H) is an autosomal recessive genetic disorder.
Hurler Syndrome (MPS1H) is a severe metabolic disorder caused by a deficiency in the enzyme alpha-L-iduronidase, which is essential for breaking down complex sugars called glycosaminoglycans (GAGs). This deficiency is caused by mutations in the IDUA gene, resulting in the toxic accumulation of GAGs within the body's cells and tissues.
Hurler Syndrome (MPS1H) is an autosomal recessive genetic disorder. Every individual has two copies of the IDUA gene—one inherited from each parent. For a child to develop Hurler Syndrome (MPS1H), they must inherit two non-functioning or mutated copies of the IDUA gene. If a person inherits only one mutated copy, they are a carrier and typically do not show symptoms of the disease.
Think of the body’s cells as a house that produces trash (glycosaminoglycans). In a healthy individual, the alpha-L-iduronidase enzyme acts as the "trash collector" that breaks down these sugar chains. In patients with Hurler Syndrome (MPS1H), the lack of this enzyme means the "trash" accumulates, eventually overflowing and damaging the cells and organs. This progressive buildup leads to the systemic symptoms seen in Hurler Syndrome (MPS1H).
No, there are no known environmental triggers, infections, or autoimmune factors that cause Hurler Syndrome (MPS1H). It is purely a genetic condition determined at the moment of conception. The primary factors involved include:
While the cause of Hurler Syndrome (MPS1H) is well-understood, researchers are actively investigating better therapeutic outcomes. Current studies focus on optimizing hematopoietic stem cell transplantation (HSCT) and exploring gene therapy to introduce functional copies of the IDUA gene into the patient's cells to restore enzyme production.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.